Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.
2 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.Sub-event
Edwards Lifesciences focuses on developing products for advanced cardiovascular diseases.1 source
Keep exploring
The entities involved
-
Edwards Lifesciences
American medical technology company
Coverage
Newest first; wire copies grouped- BarchartEdwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector? Valued at approximately $47.8 billion by market capitalization, California-based Edwards Lifesciences Corporation (EW) develops
- Medical Device NetworkESC 2025: Structural heart disease guidelines updated following Edwards trial results The European Society of Cardiology (ESC) has updated its care guidelines for valvular heart disease, due in large